MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

ImmunityBio Inc

Closed

SectorHealthcare

2.95 -3.28

Overview

Share price change

24h

Current

Min

2.9

Max

3.04

Key metrics

By Trading Economics

Income

27M

-59M

Sales

1.4M

7.6M

EPS

-0.08

Profit margin

-783.62

Employees

680

EBITDA

946K

-40M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+99.34% upside

Dividends

By Dow Jones

Next Earnings

7 May 2025

Market Stats

By TradingEconomics

Market Cap

273M

2.7B

Previous open

6.23

Previous close

2.95

News Sentiment

By Acuity

21%

79%

47 / 386 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

ImmunityBio Inc Chart

Past performance is not a reliable indicator of future results.

Related News

29 Jan 2025, 15:59 UTC

Major Market Movers

ImmunityBio Shares Rise After Collaboration, Supply Agreement With BeiGene

23 Apr 2024, 10:51 UTC

Major Market Movers

ImmunityBio Shares Soar Premarket on FDA Nod for Anktiva

24 Oct 2024, 13:50 UTC

Acquisitions, Mergers, Takeovers

This Biotech Stock Could Rocket 800%, Analyst Says -- Barrons.com

Peer Comparison

Price change

ImmunityBio Inc Forecast

Price Target

By TipRanks

99.34% upside

12 Months Forecast

Average 6.08 USD  99.34%

High 8 USD

Low 4.25 USD

Based on 3 Wall Street analysts offering 12 month price targets forImmunityBio Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

2

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

2.92 / 3.26Support & Resistance

Short Term

Very Strong Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

47 / 386 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About ImmunityBio Inc

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.